R. Oballa

发表

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

J. R. Somoza, Dan Wang, J. Falgueyret, 2005, Journal of medicinal chemistry.

Remote, 1,5-anti stereoinduction in the boron-mediated aldol reactions of β-oxygenated methyl ketones

R. Oballa, K. Gibson, I. Paterson, 1996 .

Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits

L. Duong, R. Oballa, D. Kimmel, 2013, BMC Musculoskeletal Disorders.

A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.

J. Falgueyret, J. Palmer, C. Bryant, 2003, Journal of medicinal chemistry.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

J. Falgueyret, R. Rydzewski, M. Percival, 2001, Journal of medicinal chemistry.

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry.

R. Oballa, T. Mauriala, K. Bateman, 2005, Rapid communications in mass spectrometry : RCM.

Effect of Cathepsin K Inhibitor Basicity on in Vivo Off-Target Activities

L. Duong, M. Percival, R. Oballa, 2008, Molecular Pharmacology.

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.

J. Falgueyret, R. Oballa, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.

R. Oballa, J. Guay, Sébastien Guiral, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

J. Falgueyret, R. Oballa, J. Guay, 2010, Bioorganic & medicinal chemistry letters.

Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors.

C. Bryant, R. Rydzewski, R. Oballa, 2002, Bioorganic & medicinal chemistry.

Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors

R. Oballa, K. Bateman, C. Li, 2011, Journal of Lipid Research.

2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.

J. Falgueyret, R. Oballa, P. Tawa, 2010, Bioorganic & medicinal chemistry letters.

Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core.

C. Bayly, M. Percival, R. Oballa, 2007, Bioorganic & medicinal chemistry letters.

Comparison of MALDI to ESI on a triple quadrupole platform for pharmacokinetic analyses.

R. Oballa, D. Volmer, T. Mauriala, 2007, Analytical chemistry.

A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.

Jean-François Truchon, Christopher I Bayly, C. Bayly, 2007, Bioorganic & medicinal chemistry letters.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

J. Falgueyret, J. Palmer, M. Venuti, 2008, Bioorganic & medicinal chemistry letters.

Stereocontrolled Total Synthesis of (+)-Altohyrtin A/Spongistatin 1.

A. P. Hodgson, R. Oballa, K. Gibson, 2001, Angewandte Chemie.

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

David A. Powell, Lei Zhang, R. Oballa, 2011, Journal of medicinal chemistry.

Stereocontrolled Total Synthesis of (+)-Altohyrtin A/Spongistatin 1.

A. P. Hodgson, R. Oballa, K. Gibson, 2001, Angewandte Chemie.

Synthesis of Cytotoxic Marine Macrolides: An Aldol-Based Approach to Spongistatin 1 (Altohyrtin A)

R. Oballa, K. Gibson, I. Paterson, 1999 .

Studies in marine macrolide synthesis: Synthesis of the C1C15 subunit of spongistatin 1 (altohyrtin A) and 15,16-anti aldol coupling reactions

R. Oballa, I. Paterson, 1997 .

Iterative annulations leading to functionalized tricyclo-[6.4.0.01,5]dodecanes and tricyclo[5.3.2.04,11]dodecanes

R. Oballa, E. Piers, 1995 .

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.

J. Falgueyret, R. Rydzewski, M. Percival, 2001, Journal of medicinal chemistry.

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.

R. Oballa, Qingping Wang, F. Massé, 2009, Bioorganic & medicinal chemistry letters.

Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.

C. Bayly, J. Falgueyret, M. Percival, 2008, Journal of Medicinal Chemistry.

Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors.

C. Bayly, J. Falgueyret, M. Percival, 2004, Bioorganic & medicinal chemistry letters.

Practical asymmetric synthesis of a potent Cathepsin K inhibitor. Efficient palladium removal following Suzuki coupling.

P. Prasit, R. Oballa, E. Grabowski, 2003, The Journal of organic chemistry.

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity.

J. Falgueyret, M. Percival, R. Oballa, 2005, Journal of medicinal chemistry.

MSE with mass defect filtering for in vitro and in vivo metabolite identification.

Mark Wrona, Kevin P Bateman, R. Oballa, 2007, Rapid communications in mass spectrometry : RCM.

Discovery of Aryl Sulfonamides as Isoform-Selective Inhibitors of NaV1.7 with Efficacy in Rodent Pain Models.

Shifeng Liu, R. Oballa, D. Sutherlin, 2016, ACS medicinal chemistry letters.

Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes

Andrew Ridsdale, John Paul Pezacki, Rodney K. Lyn, 2014, Scientific Reports.

Total syntheses of the sesquiterpenoids (+)-trans-dracunculifoliol and (+)-4-hydroxyoppositan-7-one

R. Oballa, R. Carson, J. Robichaud, 2005 .

Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis

L. Duong, R. Oballa, G. Wesolowski, 2014, Molecular Cancer Therapeutics.

Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria.

W. Lowther, R. Oballa, A. Caron, 2021, ACS medicinal chemistry letters.

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.

R. Oballa, S. Léger, Sébastien Guiral, 2012, Bioorganic & medicinal chemistry letters.

Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.

J. R. Somoza, C. Bayly, J. Palmer, 2006, Journal of Medicinal Chemistry.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.

Lei Zhang, Serge Leger, Jean-Philippe Leclerc, 2011, Bioorganic & medicinal chemistry letters.

Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.

R. Oballa, R. Gordon, J. Guay, 2011, Bioorganic & medicinal chemistry letters.

The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7.

R. Oballa, C. Cohen, Shaoyi Sun, 2014, Bioorganic & medicinal chemistry letters.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

J. Falgueyret, M. Percival, R. Oballa, 2010, Bioorganic & medicinal chemistry letters.